16. Crow-Fukase syndrome
12 clinical trials, 18 drugs (DrugBank: 8 drugs), 5 drug target genes, 79 drug target pathways
Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-003202-33-IT (EUCTR) | 15/09/2009 | 17/11/2009 | Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002 | Evaluation of efficacy and safety of Lenalidomide (Revlimid) in patients with POEMS Syndrome - ONC-2008-002 | POEMS SYNDROME MedDRA version: 9.1;Level: SOC;Classification code 10029205 | Trade Name: REVLIMID*21CPS 25MG INN or Proposed INN: Lenalidomide | ISTITUTO CLINICO HUMANITAS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 2 | NCT00971685 (ClinicalTrials.gov) | July 2009 | 3/9/2009 | The Treatment of Lenalidomide in Patients With POEMS Syndrome | Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome | POEMS Syndrome | Drug: Lenalidomide and dexamethasone | Istituto Clinico Humanitas | NULL | Recruiting | 18 Years | N/A | Both | 16 | Phase 2 | Italy |